Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00921973 · ClinicalTrials.gov registry record · Phase 1
Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults
A Phase 1 study, sponsored by VaxInnate Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00921973 is a Phase 1 study that has completed, run by VaxInnate Corporation. The registered enrollment target is 80 participants.
The verdict
NCT00921973, a Phase 1 study, has completed, sponsored by VaxInnate Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The study will assess the safety, reactogenicity, and tolerability of VAX102 when given with Trivalent Inactivated Influenza Vaccine (TIV) delivered in the same arm as two separate IM injections in healthy adults 18 to 49 years. The investigators will measure the immunogenicity of the VAX102 when given with TIV and the antibody response to TIV when given with VAX102 compared to TIV alone.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VAX102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00921973
The ClinicalTrials.gov registry entry for NCT00921973 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VaxInnate Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00921973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00921973 about?
NCT00921973 is a clinical study titled "Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults". The study will assess the safety, reactogenicity, and tolerability of VAX102 when given with Trivalent Inactivated Influenza Vaccine (TIV) delivered in the same arm as two separate IM injections in healthy adults 18 to 49 years. The investigators will measure the immunogenicity of the VAX102 when gi...
What is the current status of trial NCT00921973?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2009-06. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00921973?
The interventions under investigation include: Placebo (BIOLOGICAL), VAX102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00921973?
This trial is sponsored by VaxInnate Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.